Evidence map›Paper›PMID 40769988›Full record

ArticleScientific reports2025

Shadowless amyloid imaging with quantitative birefringence contrast.

Toshitaka Wakayama, Shun Yokouchi, Hidekazu Kayano, Takeshi Higashiguchi

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Toshitaka WakayamaFaculty of Health and Medical Care, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama, Japan. wakayama@saitama-med.ac.jp.
Shun YokouchiFaculty of Health and Medical Care, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama, Japan.
Hidekazu KayanoFaculty of Health and Medical Care, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama, Japan.
Takeshi HigashiguchiFaculty of Engineering, Utsunomiya University, 2 7-1-2 Yoto, Utsunomiya, Tochigi, Japan.

Funding

Amada Foundation AF-2023226-B3Japan Society for the Promotion of Science 23K28345
6 · The paper itself

Abstract

In the diagnosis of amyloidosis using Congo red staining, the apple-green birefringence observed under crossed Nicols has been considered the gold standard for over fifty years. However, a variety of colors, including orange and blue, not just apple-green, are observed in clinical fields. Moreover, the issue of polarization shadows under the crossed Nicols also impedes detailed observations of amyloid deposits, such as senile plaques. The introduction of advanced birefringence microscopes into clinical settings is also limited due to equipment-related challenges. In this study, we propose a simple but robust method that equips a standard optical microscope with polarizers to determine the birefringence and dichroism of Congo red-stained amyloid deposits. By employing an innovative image processing technique that averages multiple images, we achieved a correlation of over 95% with the birefringence distribution. This approach not only minimizes commonly encountered polarization shadows but also enhances the clarity and accuracy of amyloidosis diagnoses. Our strategy simplifies the diagnostic process and facilitates the incorporation of quantitative imaging technologies into routine pathological practices. The findings suggest that characteristic birefringence, independent of azimuthal angle, serves as a reliable marker for amyloidosis, potentially revolutionizing diagnostic protocols in the field.

Indexed as

AmyloidAmyloidosisBirefringenceCongo RedHumansImage Processing, Computer-AssistedMicroscopy, PolarizationAmyloidCongo Red

Identifiers

PMID40769988
PMCPMC12328739

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.